Related Experiment Video

Updated: Apr 20, 2026

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

1.1K

[FLT3 targeting treatment in acute myeloid leukemia]

Xue Liu1, Yan Yi1, Jiankai Shen1

  • 1Division of Hematology, Second Xiangya Hospital, Central South University, Changsha 410011, China.

Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi
|November 25, 2014
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

959
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.8K

Related Experiment Videos

Last Updated: Apr 20, 2026

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

1.1K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

959
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
1.8K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

74
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
74

Articles linked to this work by shared authors, journal, and citation graph.

Risk factors and management strategies in acute promyelocytic leukemia: a real-world single-center retrospective study.

Frontiers in medicine·2026

Clonal origin tracing and integrated biomarker analysis in a JAK2V617F-positive essential thrombocythemia patient progressing to T-cell acute lymphoblastic leukemia.

Haematologica·2026

Novel compound heterozygous ITGA2B mutations in Glanzmann thrombasthenia associated with adolescent osteoporosis.

Platelets·2026

IRF4 (MUM1) in B-cell malignancies: molecular mechanisms, biological functions, and clinical implications.

Pathology·2025

Raw lacquer-associated familial chronic myelomonocytic leukemia with multi-hit TET2 mutations.

Frontiers in oncology·2025

Germline mutation in Cbl proto-oncogene B is associated with inherited thrombocytopenia and predisposes megakaryocytes to ferroptosis.

Biochimica et biophysica acta. Molecular basis of disease·2025

[Application and challenges of the clinical decision support system in hematological diseases].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi·2026

[Current status and progress in the diagnosis and treatment of monomorphic epitheliotropic intestinal T-cell lymphoma].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi·2026

[Prognostic significance of IKZF1 alterations in acute B-lymphoblastic leukemia and the choice of transplantation strategy].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi·2026

[Somatic and immune profiling of chemotherapy-associated aplastic anemia: a comparison with primary aplastic anemia and cancer without aplastic anemia].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi·2026

[Glofitamab for relapsed/refractory B-cell lymphoma: analysis of efficacy and influencing factors].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi·2026

[Construction of a methionine metabolism-related prognostic signature and the effect of targeting methionine metabolism on diffuse large B-cell lymphoma].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us